IDEAS home Printed from https://ideas.repec.org/a/spr/hecrev/v3y2013i1p1-1210.1186-2191-1991-3-18.html
   My bibliography  Save this article

A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

Author

Listed:
  • Anthony Bentley
  • Ivana Filipovic
  • Katherine Gooch
  • Katharina Büsch

Abstract

Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources. Copyright Bentley et al.; licensee Springer. 2013

Suggested Citation

  • Anthony Bentley & Ivana Filipovic & Katherine Gooch & Katharina Büsch, 2013. "A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom," Health Economics Review, Springer, vol. 3(1), pages 1-12, December.
    • Handle: RePEc:spr:hecrev:v:3:y:2013:i:1:p:1-12:10.1186/2191-1991-3-18
    DOI: 10.1186/2191-1991-3-18
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1186/2191-1991-3-18
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1186/2191-1991-3-18?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. John S. Sampalis & Joanne Langley & Xavier Carbonell-Estrany & Bosco Paes & Karel O'Brien & Upton Allen & Ian Mitchell & José Figueras Aloy & Carmen Pedraz & Andrea F. Michaliszyn, 2008. "Development and Validation of a Risk Scoring Tool to Predict Respiratory Syncytial Virus Hospitalization in Premature Infants Born at 33 through 35 Completed Weeks of Gestation," Medical Decision Making, , vol. 28(4), pages 471-480, July.
    2. Mark Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier, 2007. "Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children," PharmacoEconomics, Springer, vol. 25(1), pages 55-71, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Gareth Thomas, 2018. "A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 177-187, March.
    2. Koen B Pouwels & Sefika E Bozdemir & Selen Yegenoglu & Solmaz Celebi & E David McIntosh & Serhat Unal & Maarten J Postma & Mustafa Hacimustafaoglu, 2016. "Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data," PLOS ONE, Public Library of Science, vol. 11(9), pages 1-15, September.
    3. Colette Mankowski & Sachin Patel & David Trueman & Anthony Bentley & Chris Poole, 2016. "Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-16, March.
    4. Ralph Schmidt & Istvan Majer & Natalia García Román & Alejandra Rivas Basterra & ElizaBeth Grubb & Constancio Medrano López, 2017. "Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways," Health Economics Review, Springer, vol. 7(1), pages 1-14, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Mark Nuijten & Wolfgang Wittenberg, 2010. "Cost effectiveness of palivizumab in Spain: an analysis using observational data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 105-115, February.
    2. Maarten O Blanken & Hendrik Koffijberg & Elisabeth E Nibbelke & Maroeska M Rovers & Louis Bont & on behalf of the Dutch RSV Neonatal Network, 2013. "Prospective Validation of a Prognostic Model for Respiratory Syncytial Virus Bronchiolitis in Late Preterm Infants: A Multicenter Birth Cohort Study," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-6, March.
    3. Koen B Pouwels & Sefika E Bozdemir & Selen Yegenoglu & Solmaz Celebi & E David McIntosh & Serhat Unal & Maarten J Postma & Mustafa Hacimustafaoglu, 2016. "Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data," PLOS ONE, Public Library of Science, vol. 11(9), pages 1-15, September.
    4. Gareth Thomas, 2018. "A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 177-187, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:hecrev:v:3:y:2013:i:1:p:1-12:10.1186/2191-1991-3-18. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/13561 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.